Twinbeech Capital LP Invests $3.89 Million in Encompass Health Co. (NYSE:EHC)

Twinbeech Capital LP purchased a new position in shares of Encompass Health Co. (NYSE:EHC) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 42,154 shares of the company’s stock, valued at approximately $3,893,000.

Other large investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Encompass Health by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company’s stock valued at $59,544,000 after buying an additional 4,345 shares in the last quarter. Merit Financial Group LLC purchased a new position in shares of Encompass Health during the 4th quarter valued at $374,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Encompass Health during the 4th quarter valued at $4,160,000. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after buying an additional 137 shares in the last quarter. Finally, US Bancorp DE lifted its stake in shares of Encompass Health by 9.6% during the 4th quarter. US Bancorp DE now owns 1,380 shares of the company’s stock valued at $127,000 after buying an additional 121 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Insider Buying and Selling at Encompass Health

In other news, CEO Mark J. Tarr sold 118,384 shares of the company’s stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total value of $14,387,207.52. Following the completion of the sale, the chief executive officer now owns 527,070 shares of the company’s stock, valued at approximately $64,054,817.10. This represents a 18.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Patrick Darby sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the sale, the executive vice president now directly owns 79,710 shares of the company’s stock, valued at $9,149,910.90. The trade was a 11.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 132,663 shares of company stock valued at $16,034,082 in the last three months. Company insiders own 2.00% of the company’s stock.

Encompass Health Stock Performance

Encompass Health stock opened at $121.67 on Wednesday. The company’s 50-day moving average price is $106.53 and its 200-day moving average price is $101.04. Encompass Health Co. has a twelve month low of $82.74 and a twelve month high of $121.96. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The company has a market cap of $12.26 billion, a PE ratio of 27.28, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91.

Encompass Health (NYSE:EHC) last posted its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.18. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same period in the previous year, the firm posted $1.12 EPS. The business’s quarterly revenue was up 10.6% on a year-over-year basis. On average, equities research analysts forecast that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be given a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 annualized dividend and a yield of 0.56%. Encompass Health’s dividend payout ratio (DPR) is 14.05%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. William Blair restated an “outperform” rating on shares of Encompass Health in a research note on Friday, February 7th. UBS Group lifted their price target on shares of Encompass Health from $117.00 to $130.00 and gave the company a “buy” rating in a report on Monday, April 28th. StockNews.com upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Sunday, May 11th. Truist Financial reiterated a “buy” rating and issued a $135.00 price target (up from $116.00) on shares of Encompass Health in a report on Monday, April 28th. Finally, Royal Bank of Canada lifted their price target on shares of Encompass Health from $110.00 to $125.00 and gave the company an “outperform” rating in a report on Monday, April 28th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Encompass Health currently has an average rating of “Buy” and an average price target of $120.86.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.